Outpatient Drugs Payment Policy

Size: px
Start display at page:

Download "Outpatient Drugs Payment Policy"

Transcription

1 Policy Outpatient Drugs Payment Policy Fallon Community Health Plan (FCHP) reimburses contracted providers for the provision of covered FDA-approved non-self administered drugs when given in an outpatient setting. This policy also applies to drugs administered by a provider via an implantable drug delivery system and to brachytherapy sources. FCHP anticipates that providers will administer drugs to members in such a way that they can use drugs most efficiently, in a clinically appropriate manner. FCHP does not reimburse for that portion of a multi-use vial of medication that is not administered to FCHP members including, but not limited to, those that are determined to be contaminated, wasted or unused. When drugs are eligible for separate reimbursement, FCHP s reimbursement is for pharmaceuticals which are administered to a FCHP member, only up to the next incremental Level II HCPCS code unit. Benefits application FCHP Direct Care/FCHP Select Care Commonwealth Care Companion Care FCHP MassHealth Fallon Preferred Care PPO Fallon Senior Plan HMO Fallon Senior Plan PPO Summit ElderCare NaviCare Reimbursement FCHP anticipates that providers will administer drugs to members in such a way that they can use drugs most efficiently, in a clinically appropriate manner. FCHP reimburses the provision of covered FDA-approved non-self administered drugs when given in an outpatient setting. FCHP s reimbursement is for pharmaceuticals which are administered to a FCHP member, only up to the next incremental Level II HCPCS code unit. FCHP does not reimburse for that portion of a multi-use vial of medication that is not administered to FCHP members including, but not limited to, those that are determined to be contaminated, wasted or unused, FCHP does not reimburse for that portion of a single-use vial of medication that is not administered to a FCHP member including, but not limited to, those that are determined to be contaminated, wasted or unused, unless documentation within the patient s medical record file indicates the date, time, and name of clinical staff who wasted the portion of medication within a single-use vial. FCHP anticipates that the provider will utilize the most appropriate sized single-use vial or combination of single-use vials to deliver the ordered dose of medication and minimize waste. Outpatient Drugs Payment Policy Page 1 of 13 effective 07/01/2014

2 Reimbursement will be made in accordance with contracted rates. Referral/notification/prior authorization requirements The facility or ordering physician is required to obtain prior authorization for: drugs on the list of formulary medications that require prior authorization. This list can be found in the Provider Pharmacy section of the FCHP Web site and drugs with HCPCS codes found on the List of Procedures Requiring Prior Authorization located in the Managing Patient Care section of the Provider Manual under PCP Referral and Plan Prior Authorization Process. Pharmacy Prior Authorization Forms must be completed and faxed to For urgent situations, please call and select option 5. Billing/coding guidelines Bill pharmaceuticals with both the NDC number and the appropriate Level II HCPCS codes; bill with a count when indicated. As of February 1, 2013, MassHealth requires NDC information on all Single-Source Drugs as defined by CMS, with the exceptions listed below: 1. Inpatient Claims 2. Outpatient claims that are part of a bundled rate or global fee 3. Claims purchased under the 340B drug discount program/claims from providers listed on the Office of Pharmacy Affairs website as participating in Medicaid. 4. Radiopharmaceuticals** 5. Contrast media 6. Vaccines 7. Devices **CMS plans to issue new guidance to require NDC information for radiopharmaceuticals. With the exception of the scenarios listed above, claims for services for FCHP members enrolled through MassHealth that are submitted without NDC information will be denied. In order to be paid, a claim adjustment request with the NDC information will need to be submitted to FCHP. MassHealth will supply a list of HCPCS that require NDC codes to FCHP. This list is exhibit A of this policy. This list will be updated quarterly beginning in the second quarter of calendar year Pharmaceutical Waste For multi-use vials, bill only for the portion of the medication administered to the member; wasted pharmaceutical will not be reimbursed. FCHP does not require but will accept modifier JW drug amount discarded/not administered to any patient to identify drugs where the dosage contained in the single-use vial is greater than ordered and/or administered. FCHP anticipates that providers will administer drugs to members in such a way that they can use drugs most efficiently, in a clinically appropriate manner. FCHP also anticipates that the provider will utilize the most appropriate sized single-use vial or combination of single-use vials to deliver the ordered dose of medication and minimize waste. FCHP s reimbursement is for pharmaceuticals which are administered to a FCHP member, only up to the next incremental Level II HCPCS code unit. Wasted pharmaceutical from a single-use vial will be reimbursed when the wasted medication is documented as such within the patient s medical record. Such documentation should include the date, time and name of the clinical staff wasting the pharmaceutical, as well as the amount of wasted medication. Documentation of waste must be retained within the patient s medical record and/or made available to FHCP audit representatives upon request. Outpatient Drugs Payment Policy Page 2 of 13

3 Claims submitted with Revenue Code 0636 must include the HCPCS code. FCHP reserves the right to audit to verify payment accuracy. Neither FCHP nor FCHP members can be held financially responsible for any denied payments for pharmaceuticals that were not administered. Electronic claim submitters Submit both the HCPCS J code and NDC number in the HIPAA-compliant format. Paper claim submitters CMS-1500 form Bill both the HCPCS J code and NDC number in field 24D; place the NDC number under the Level II HCPCS code; bill units in field 24G. UB-04 form Bill the Level II HCPCS code in field locator 44; the NDC number in field locator 43; service units in field locator 46. Place of service This policy applies to services rendered in the outpatient setting. Policy history Origination date: 11/1/09 Previous revision date(s): 07/01/2010 updated language in the Policy, Reimbursement and Billing/coding guidelines sections to indicate policy and process regarding pharmaceutical waste. 01/01/ Updated billing/coding guidelines to add discussion about revenue code /01/ Removed requirement for itemized invoice with revenue code /1/2012 Removed requirement to submit modifier JW - drug amount discarded and that the amount discarded from single-use vial drugs will not be reimbursed. 02/01/2013 Updated NDC billing requirements for members enrolled through MassHealth. 09/01/ Updated discussion of drug waste and reimbursement for multi vs. single use vials. Connection date & details: May 2014 Clarified discussion about drug waste. This payment policy has been developed to provide information regarding general billing, coding and documentation guidelines for FCHP. Even though this payment policy may indicate that a particular service or supply is considered covered, specific provider contract terms and/or member individual benefit plans may apply and this policy is not a guarantee of payment. FCHP reserves the right to apply this payment policy to all FCHP companies and subsidiaries. FCHP routinely verifies that charges billed are in accordance with the guidelines stated in this payment policy and are appropriately documented in the medical records. Payments are subject to postpayment audits and retraction of overpayments. Outpatient Drugs Payment Policy Page 3 of 13

4 Exhibit A HCPCS that require NDC codes for MassHealth MassHealth requires NDC information on all Single-Source Drugs as defined by CMS, with some exceptions. MassHealth will supply a list of HCPCS that require NDC codes to FCHP. This list is exhibit A of this policy. This list will be updated quarterly beginning in the second quarter of calendar year Claims for services for FCHP members enrolled through MassHealth with the following HCPCS codes that are submitted without NDC information will be denied. In order to be paid, a claim adjustment request with the NDC information will need to be submitted to FCHP. HCPCS SHORT DESCRIPTOR DRUG NAME HCPCS DOSAGE J0129 Abatacept injection Abatacept 10 MG J0130 Abciximab injection Reopro 10 MG J0135 Adalimumab injection Humira 20 MG J0152 Adenosine injection Adenoscan 30 MG J0180 Agalsidase beta injection Fabrazyme 1 MG J0207 Amifostine Ethyol 500 MG J0215 Alefacept Amevive 0.5 MG J0220 Alglucosidase alfa injection Myozyme 10 MG J0221 Lumizyme injection Lumizyme 10 MG J0256 Alpha 1 proteinase inhibitor Aralast NP 10 MG J0256 Alpha 1 proteinase inhibitor Zemaira 10 MG J0257 Glassia injection GLASSIA 10 MG J0287 Amphotericin b lipid complex Abelcet 10 MG J0288 Ampho b cholesteryl sulfate Amphotec 10 MG J0289 Amphotericin b liposome inj Ambisome 10 MG J0348 Anidulafungin injection ERAXIS 1 MG J0400 Aripiprazole injection Aripiprazole IM inj 0.25 MG J0470 Dimecaprol injection Bal In Oil 100 MG J0480 Basiliximab Simulect 20 MG J0490 Belimumab injection BENLYSTA 10 MG J0515 Inj benztropine mesylate Cogentin 1 MG J0558 PenG benzathine/procaine inj Bicillin CR Pediatric 100,000 UNITS J0558 PenG benzathine/procaine inj BICILLIN C-R 100,000 UNITS J0583 Bivalirudin Angiomax 1 MG J0585 Injection,onabotulinumtoxinA Botox Cosmetic 1 UNIT J0585 Injection,onabotulinumtoxinA Botox 1 UNIT J0586 AbobotulinumtoxinA Dysport 5 Unit J0587 Inj, rimabotulinumtoxinb Myobloc 100 UNITS J0588 Incobotulinumtoxin A XEOMIN 1 UNIT J0594 Busulfan injection BUSULFAN 1 MG Outpatient Drugs Payment Policy Page 4 of 13

5 J0597 C-1 esterase, berinert BERINERT 10 UNITS J0598 C-1 esterase, cinryze Cinryze 10 UNITS J0630 Calcitonin salmon injection Miacalcin 400 UNITS J0637 Caspofungin acetate Cancidas 5 MG J0638 Canakinumab injection ILARIS 1 MG J0641 Levoleucovorin injection Levoleucovorin Calcium 0.5 MG J0697 Sterile cefuroxime injection Zinacef In D5W 750 MG J0697 Sterile cefuroxime injection Zinacef In Sterile Water 750 MG J0698 Cefotaxime sodium injection Claforan In D5W 1 GM J0698 Cefotaxime sodium injection Claforan 1 GM J0712 Ceftaroline fosamil inj Teflaro 10 MG J0713 Inj ceftazidime per 500 mg Fortaz In D5W 500 MG J0718 Certolizumab pegol inj CIMZIA 1 MG J0740 Cidofovir injection Vistide 375 MG J0743 Cilastatin sodium injection Primaxin Iv 250 MG J0744 Ciprofloxacin iv CIPROFLOXACIN 200 MG J0775 Collagenase, clost hist inj XIAFLEX (collagenase clostridium histolyticum) 0.01 MG J0850 Cytomegalovirus imm IV /vial CYTOGAM PER VIAL J0878 Daptomycin injection Cubicin 1 MG J0881 Darbepoetin alfa, non-esrd Aranesp 1 MCG J0882 Darbepoetin alfa, esrd use Aranesp 1 MCG J0885 Epoetin alfa, non-esrd Epogen 1000 UNITS J0885 Epoetin alfa, non-esrd Procrit 1000 UNITS J0886 Epoetin alfa 1000 units ESRD Epogen 1000 UNITS J0886 Epoetin alfa 1000 units ESRD Procrit 1000 UNITS J0894 Decitabine injection decitabine 1 MG J0897 Denosumab injection Prolia 1 MG J0897 Denosumab injection XGEVA 1 MG J1051 Medroxyprogesterone inj Depo-Provera 50 MG J1170 Hydromorphone injection Hydromorphone Hcl 4 MG J1205 Chlorothiazide sodium inj Diuril Iv 500 MG J1230 Methadone injection Methadone Hcl 10 MG J1260 Dolasetron mesylate Anzemet 10 MG J1267 Doripenem injection DORIBAX 10 MG J1270 Injection, doxercalciferol Hectorol 1 MCG J1290 Ecallantide injection KALBITOR 1 MG J1300 Eculizumab injection Soliris 10 MG J1325 Epoprostenol injection Epoprostenol 0.5 MG J1327 Eptifibatide injection Integrilin 5 MG J1335 Ertapenem injection Invanz 500 MG Outpatient Drugs Payment Policy Page 5 of 13

6 J1410 Inj estrogen conjugate 25 MG Premarin 25 MG J1438 Etanercept injection Enbrel (Etanercept) 25 MG J1438 Etanercept injection Enbrel 25 MG J1440 Filgrastim 300 mcg injection Neupogen 300 MCG J1441 Filgrastim 480 mcg injection Neupogen 480 MCG J1451 Fomepizole, 15 mg Antizol 15 MG EMEND FOR INJECTION J1453 Fosaprepitant injection 150MG 1 MG J1453 Fosaprepitant injection EMEND FOR INJECTION 1 MG J1459 Inj IVIG privigen 500 mg Privigen 500 MG J1557 Gammaplex injection GAMMAPLEX 500 MG J1559 Hizentra injection Hizentra 100 MG J1561 Gamunex, Gamunex-C, Gammaked Gamunex 500 MG J1561 Gamunex, Gamunex-C, Gammaked Gamunex-C 500 MG J1566 Immune globulin, powder Gammagard S/D 500 MG J1566 Immune globulin, powder Carimune Nf 500 MG J1568 Octagam injection Octagam 5%, 5 g in 100 ml 500 MG J1568 Octagam injection Octagam 5%, 25 g in 500 ml 500 MG J1568 Octagam injection Octagam 5%, 2.5 g in 50 ml 500 MG J1568 Octagam injection Octagam 5%, 1 g in 20 ml 500 MG J1568 Octagam injection Octagam 500 MG J1569 Gammagard liquid injection GAMMAGARD LIQUID 500 MG J1571 Hepagam b im injection CBI HepaGam B 1 ml 0.5 ML J1571 Hepagam b im injection CBI HepaGam B 5 ml 0.5 ML J1571 Hepagam b im injection Nova HepaGam B 1 ml 0.5 ML J1571 Hepagam b im injection Nova HepaGam B 5 ml 0.5 ML J1572 Flebogamma injection Flebogamma DIF 500 MG J1572 Flebogamma injection FLEBOGAMMA 10% DIF 500 MG J1573 Hepagam b intravenous, inj Nova HepaGam B 1 ml 0.5 ML J1573 Hepagam b intravenous, inj Nova HepaGam B 5 ml 0.5 ML J1573 Hepagam b intravenous, inj CBI HepaGam B 1 ml 0.5 ML J1573 Hepagam b intravenous, inj CBI HepaGam B 5 ml 0.5 ML GLUCAGON J1610 Glucagon hydrochloride/1 MG HYDROCHLORIDE 1 MG J1610 Glucagon hydrochloride/1 MG Glucagon Emergency 1 MG J1640 Hemin, 1 mg Panhematin 1 MG J1645 Dalteparin sodium Fragmin 2500 IU J1650 Inj enoxaparin sodium Lovenox 10 MG J1670 Tetanus immune globulin inj HYPERTET S/D 250 UNITS J1740 Ibandronate sodium injection BONIVA 1 MG J1740 Ibandronate sodium injection Ibandronate sodium 1 MG Outpatient Drugs Payment Policy Page 6 of 13

7 J1743 Idursulfase injection Idursulfase 1 MG J1745 Infliximab injection Remicade 10 MG J1750 Inj iron dextran Dexferrum 50 MG J1756 Iron sucrose injection Venofer 1 MG J1786 Imuglucerase injection Cerezyme 10 UNITS J1815 Insulin injection Humalog 5 UNITS J1815 Insulin injection Humalog Pen 5 UNITS J1815 Insulin injection Humulin 70/30 5 UNITS J1815 Insulin injection Humulin 70/30 Pen 5 UNITS J1815 Insulin injection HUMULIN N 5 UNITS J1815 Insulin injection Humulin N Pen 5 UNITS J1815 Insulin injection Humulin R 5 UNITS J1815 Insulin injection Novolog Mix 70/30 Flexpen 5 UNITS J1815 Insulin injection Novolin N 5 UNITS J1815 Insulin injection Novolog Penfill 5 UNITS J1815 Insulin injection Novolin R 5 UNITS J1815 Insulin injection Novolog 5 UNITS J1815 Insulin injection Novolog Flexpen 5 UNITS J1815 Insulin injection Novolog Mix 70/30 5 UNITS J1815 Insulin injection Humalog Mix 75/25 5 UNITS J1815 Insulin injection Novolin 70/30 5 UNITS J1817 Insulin for insulin pump use Novolog Penfill 50 UNITS J1817 Insulin for insulin pump use Novolog Mix 70/30 Flexpen 50 UNITS J1817 Insulin for insulin pump use Novolog Mix 70/30 50 UNITS J1817 Insulin for insulin pump use Novolog Flexpen 50 UNITS J1817 Insulin for insulin pump use Novolog 50 UNITS J1817 Insulin for insulin pump use Novolin R 50 UNITS J1817 Insulin for insulin pump use Novolin N 50 UNITS J1817 Insulin for insulin pump use Novolin 70/30 50 UNITS J1817 Insulin for insulin pump use Humulin R 50 UNITS J1817 Insulin for insulin pump use Humulin N Pen 50 UNITS J1817 Insulin for insulin pump use Humulin N 50 UNITS J1817 Insulin for insulin pump use Humulin 70/30 Pen 50 UNITS J1817 Insulin for insulin pump use Humalog Mix 75/25 50 UNITS J1817 Insulin for insulin pump use Humalog Pen 50 UNITS J1817 Insulin for insulin pump use HUMULIN 70/30 50 UNITS J1817 Insulin for insulin pump use Humalog 50 UNITS J1930 Lanreotide injection SOMATULINE DEPOT 1 MG J1931 Laronidase injection Aldurazyme 0.1 MG J1945 Lepirudin Refludan 50 MG J1950 Leuprolide acetate /3.75 MG LUPRON DEPOT 3.75MG 3.75 MG Outpatient Drugs Payment Policy Page 7 of 13

8 J1950 J1950 Leuprolide acetate /3.75 MG Leuprolide acetate /3.75 MG LUPRON DEPOT 3-MONTH, 11.25MG LUPRON DEPOT-PED 3- MONTH, 30 MG 3.75 MG 3.75 MG J1950 Leuprolide acetate /3.75 MG Lupron Depot-Ped 11.25mg 3.75 MG J1950 Leuprolide acetate /3.75 MG LUPRON DEPOT-PED 3- MONTH, 11.25MG 3.75 MG J1953 Levetiracetam injection Levetiracetam (Keppra) 10 MG J1953 Levetiracetam injection Levetiracetam 10 MG J2020 Linezolid injection Zyvox 200 MG J2248 Micafungin sodium injection Micafungin sodium (Mycamine) 1 MG J2278 Ziconotide injection Prialt 1 MCG J2280 Inj, moxifloxacin 100 mg Avelox 100 MG J2315 Naltrexone, depot form Vivitrol 1 MG J2323 Natalizumab injection NATALIZUMAB 1 MG J2325 Nesiritide injection Natrecor 0.1 MG J2353 Octreotide injection, depot Sandostatin Lar Depot 1 MG J2355 Oprelvekin injection Neumega 5 MG J2357 Omalizumab injection Xolair 5 MG J2358 Olanzapine long-acting inj ZYPREXA RELPREVV 1 MG J2426 Paliperidone palmitate inj INVEGA SUSTENNA 1 MG J2469 Palonosetron hcl Aloxi 25 MCG J2503 Pegaptanib sodium injection Macugen 0.3 MG J2504 Pegademase bovine, 25 iu Adagen 25 IU J2505 Injection, pegfilgrastim 6mg Neulasta 6 MG J2543 Piperacillin/tazobactam NOVAPLUS ZOSYN GM J2543 Piperacillin/tazobactam Piperacillin Sodium-Tazobactam Sodium GM J2545 Pentamidine non-comp unit Nebupent 300 MG J2562 Plerixafor injection Mozobil (PLERIXAFOR) 1 MG J2597 Inj desmopressin acetate Ddavp 1 MCG J2724 Protein c concentrate CEPROTIN 10 UNITS J2730 Pralidoxime chloride inj Protopam Chloride 1 GM J2770 Quinupristin/dalfopristin Synercid 500 MG J2778 Ranibizumab injection RANIBIZUMAB 0.1 mg J2780 Ranitidine hydrochloride inj Zantac In Nacl 25 MG J2783 Rasburicase Elitek 0.5 MG J2785 Regadenoson injection Regadenoson 0.1 MG J2788 Rho d immune globulin 50 mcg Bayrho-D 50 MCG (250 IU) 300 MCG (1500 J2790 Rho d immune globulin inj HYPERRHO S/D IU) J2791 Rhophylac injection Rhophylac 100 UNITS Outpatient Drugs Payment Policy Page 8 of 13

9 J2792 Rho(D) immune globulin h, sd WINRHO SDF 100 IU J2794 Risperidone, long acting Risperdal Consta 0.5 MG J2795 Ropivacaine HCl injection Naropin 1 MG J2795 Ropivacaine HCl injection Naropin (Novaplus) 1 MG J2796 Romiplostim injection Nplate 10 MCG J2820 Sargramostim injection Leukine 50 MCG J2916 Na ferric gluconate complex Ferrlecit 12.5 MG J2997 Alteplase recombinant Cathflo Activase 1 MG J2997 Alteplase recombinant Activase 1 MG J3070 Pentazocine injection TALWIN LACTATE 30 MG J3095 Telavancin injection VIBATIV 10 MG J3101 Tenecteplase injection TNKASE 1 MG J3240 Thyrotropin injection Thyrogen 0.9 MG J3243 Tigecycline injection Tigecycline 1 MG J3246 Tirofiban HCl Aggrastat 0.25 MG J3262 Tocilizumab injection Actemra 1 MG J3285 Treprostinil injection Remodulin 1 MG J3300 Triamcinolone A inj PRS-free Triamcinolone Acetonide, Preservative Free 1 MG J3315 Triptorelin pamoate Trelstar 3.75 MG J3357 Ustekinumab injection STELARA 1 MG J3385 Velaglucerase alfa VPRIV 100 UNITS J3396 Verteporfin injection Visudyne 0.1 MG J3465 Injection, voriconazole Vfend Iv 10 MG J3471 Ovine, up to 999 USP units Vitrase 1 UNIT J3473 Hyaluronidase recombinant HYALURONIDASE 1 USP UNIT J3486 Ziprasidone mesylate Geodon 10 MG J3487 Zoledronic acid Zometa 1 MG J3488 Reclast injection Reclast 1 MG J7183 Wilate injection WILATE 1 I.U. VWF:RCO J7185 Xyntha inj XYNTHA J7186 Antihemophilic viii/vwf comp Alphanate /von Willebrand Factor Complex J7187 Humate-P, inj HUMATE-P LOW DILUENT J7189 Factor viia Novoseven RT 1 MCG J7190 Factor viii Hemofil M J7190 Factor viii MONOCLATE-P J7190 Factor viii Alphanate /von Willebrand Factor Complex J7192 Factor viii recombinant NOS Advate J7192 Factor viii recombinant NOS HELIXATE FS PER FACTOR VIII IU Outpatient Drugs Payment Policy Page 9 of 13

10 J7192 Factor viii recombinant NOS Helixate FS 3000 J7192 Factor viii recombinant NOS RECOMBINATE J7193 Factor IX non-recombinant Mononine J7193 J7193 J7193 J7194 J7194 J7194 Factor IX non-recombinant Factor IX non-recombinant Factor IX non-recombinant Factor ix complex Factor ix complex Factor ix complex Alphanine SD VF 1000 IU M2V USA Alphanine SD VF 1500 IU M2V USA Alphanine SD VF 500 IU M2V USA Profilnine SD FIX SD M2V(1000) Profilnine SD FIX SD M2V(1500) Profilnine SD FIX SD M2V(500) J7194 Factor ix complex Bebulin J7195 Factor IX recombinant Benefix J7198 Anti-inhibitor FEIBA NF J7309 Methyl aminolevulinate, top METVIXIA 1 GM J7310 Ganciclovir long act implant VITRASERT 4.5 MG J7311 Fluocinolone acetonide implt Fluocinolone acetonide implt (Retisert) Outpatient Drugs Payment Policy Page 10 of MG J7312 Dexamethasone intra implant Ozurdex 0.1 MG J7335 Capsaicin 8% patch Qutenza 10 SQ CM J7504 Lymphocyte immune globulin Atgam 250 MG J7511 Antithymocyte globuln rabbit Thymoglobulin 25 MG J7517 Mycophenolate mofetil oral Cellcept 250 MG J7518 Mycophenolic acid Myfortic 180 MG J7520 Sirolimus, oral Rapamune 1 MG J7525 Tacrolimus injection Prograf 5 MG J7605 Arformoterol non-comp unit ARFORMOTEROL 15 mcg J7606 Formoterol fumarate, inh PERFOROMIST 20 MCG J7612 Levalbuterol non-comp con Xopenex 0.5 MG J7614 Levalbuterol non-comp unit Xopenex 0.5 MG J7639 Dornase alfa non-comp unit Pulmozyme 1 MG J7665 Mannitol for inhaler Aridol 5 MG J7682 Tobramycin non-comp unit TOBI 300 MG J7686 Treprostinil, non-comp unit TYVASO (Refill Kit) 1.74 MG J7686 Treprostinil, non-comp unit TYVASO 1.74 MG J7686 Treprostinil, non-comp unit TYVASO (Starter Kit) 1.74 MG J8501 Oral aprepitant Emend Bi-pack 5 MG J8501 Oral aprepitant Emend 5 MG

11 J8501 Oral aprepitant Emend Tri-Fold 5 MG J8510 Oral busulfan Myleran 2 MG J8520 Capecitabine, oral, 150 mg Xeloda 150 MG J8521 Capecitabine, oral, 500 mg Xeloda 500 MG J8561 Oral everolimus Zortress 0.25 MG J8562 Oral fludarabine phosphate OFORTA 10 MG J8600 Melphalan oral 2 MG Alkeran 2 MG J8700 Temozolomide Temodar 5 MG J8705 Topotecan oral Topotecan, oral 0.25 mg J9010 Alemtuzumab injection Campath 10 MG J9017 Arsenic trioxide injection Trisenox 1 MG J9020 Asparaginase injection Elspar UNITS J9027 Clofarabine injection Clolar 1 MG J9031 Bcg live intravesical vac Tice Bcg 1 EA J9033 Bendamustine injection TREANDA 1 MG J9035 Bevacizumab injection Avastin 10 MG J9041 Bortezomib injection Velcade 0.1 MG J9043 Cabazitaxel injection JEVTANA 1 MG J9050 Carmustine injection BICNU 100 MG J9055 Cetuximab injection Erbitux 10 MG J9120 Dactinomycin injection Cosmegen 0.5 MG J9155 Degarelix injection Firmagon 1 MG J9160 Denileukin diftitox inj Ontak 300 MCG J9171 Docetaxel injection Taxotere 1 MG J9178 Inj, epirubicin hcl, 2 mg Epirubicin 2 MG J9179 Eribulin mesylate injection Halaven 0.1 MG J9181 Etoposide injection Etopophos 10 MG J9185 Fludarabine phosphate inj Fludara 50 MG J9202 Goserelin acetate implant Zoladex 3.6 MG J9207 Ixabepilone injection IXABEPILONE 1 MG J9208 Ifosfamide injection Ifex 1 GM J9209 Mesna injection Mesnex 200 MG J9214 Interferon alfa-2b inj Intron-A 1 MIL UNITS J9217 Leuprolide acetate suspnsion Lupron Depot 7.5 mg kit 7.5 MG J9217 J9217 J9217 Leuprolide acetate suspnsion Leuprolide acetate suspnsion Leuprolide acetate suspnsion LUPRON DEPOT 4-MONTH, 30MG LUPRON DEPOT 6-MONTH, 45MG Lupron Depot-3 month 22.5mg kit 7.5 MG 7.5 MG 7.5 MG J9217 Leuprolide acetate suspnsion Lupron Depot-Ped 15mg 7.5 MG Outpatient Drugs Payment Policy Page 11 of 13

12 J9217 Leuprolide acetate suspnsion Lupron Depot-Ped 7.5mg 7.5 MG J9225 Vantas implant Vantas implant 50 MG J9226 Supprelin LA implant Supprelin LA implant 50 MG J9228 Ipilimumab injection YERVOY 1 MG J9230 Mechlorethamine hcl inj Mustargen 10 MG J9261 Nelarabine injection ARRANON 50 MG J9263 Oxaliplatin Eloxatin 0.5 MG J9266 Pegaspargase injection ONCASPAR 1 EA J9302 Ofatumumab injection ARZERRA 10 MG J9303 Panitumumab injection PANITUMUMAB 10 MG J9305 Pemetrexed injection Alimta 10 MG J9307 Pralatrexate injection Folotyn 1 MG J9310 Rituximab injection Rituxan 100 MG J9315 Romidepsin injection Istodax (romidepsin) 1 MG J9320 Streptozocin injection Zanosar 1 GM J9328 Temozolomide injection TEMODAR IV 1 MG J9330 Temsirolimus injection TEMSIROLIMUS 1 MG J9355 Trastuzumab injection Herceptin 10 MG J9357 Valrubicin injection Valstar 200 MG J9395 Injection, Fulvestrant Faslodex 25 MG Q0138 Ferumoxytol, non-esrd Feraheme 1 MG Q0139 Ferumoxytol, esrd use Feraheme 1 MG Q0180 Dolasetron mesylate oral Anzemet 100 MG Q2017 Teniposide, 50 mg Vumon 50 MG Q2043 Sipuleucel-T auto CD54+ PROVENGE Q2046 Aflibercept injection EYLEA 1 MG Per infusion (minimum 50 million cells) Q2047 Peginesatide injection Omontys 0.1 MG Q2048 Doxil injection Doxil 10 MG Q2049 Imported Lipodox inj Lipodox 10 MG Q2049 Imported Lipodox inj Lipodox MG Q3025 IM inj interferon beta 1-a Avonex 11 MCG Q4074 Iloprost non-comp unit dose Ventavis UP TO 20 MCG Q4081 Epoetin alfa, 100 units ESRD Procrit 100 UNITS Q4081 Epoetin alfa, 100 units ESRD Epogen 100 UNITS Q9956 Inj octafluoropropane mic,ml Optison 1 ML Q9957 Inj perflutren lip micros,ml Definity 1 ML Q9965 LOCM mg/ml iodine,1ml OMNIPAQUE ML Q9965 LOCM mg/ml iodine,1ml Omnipaque ML Q9966 LOCM mg/ml iodine,1ml Visipaque 1 ML Outpatient Drugs Payment Policy Page 12 of 13

13 Q9966 LOCM mg/ml iodine,1ml Omnipaque 1 ML Q9966 LOCM mg/ml iodine,1ml Omnipaque ML Q9966 LOCM mg/ml iodine,1ml Visipaque ML Q9966 LOCM mg/ml iodine,1ml Omnipaque ML Q9967 LOCM mg/ml iodine,1ml Visipaque ML Q9967 LOCM mg/ml iodine,1ml Visipaque 1 ML Q9967 LOCM mg/ml iodine,1ml Omnipaque ML Q9967 LOCM mg/ml iodine,1ml Omnipaque ML Q9967 LOCM mg/ml iodine,1ml Omnipaque 1 ML Outpatient Drugs Payment Policy Page 13 of 13

Drug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015

Drug Name. J0129 Injection, abatacept (Orencia ), 10 mg Effective 01/01/2014. J0178 Injection, aflibercept (Eylea ), 1 mg Effective 04/01/2015 J0129 Injection, abatacept (Orencia ), 10 J0178 Injection, aflibercept (Eylea ), 1 J0256 J0257 J0585 J0586 J0587 J0588 J0597 J0641 J0717 J0800 Injection, alpha 1-proteinase inhibitor, human (Aralast NP,

More information

Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List

Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List Provider Administered Drug Program (PADP) and Physician Administered Drug VPSS List Code Drug Name Effective and/or Term Date J0129 Injection, abatacept (Orencia ), 10 mg J0178 Injection, aflibercept (Eylea

More information

Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19

Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19 Vivida Health Specialty Pharmacy Drugs (Injectable) Prior-Authorization Requirements Effective 1/1/19 All Non-Par Provider Requests Requires Authorization Regardless of Service J0178 J0180 J0202 J0205

More information

BCBS AZ ADV PLUS * CLASSIC * PREMIER For use with members associated with the BHN Network Prior Authorization List 2015

BCBS AZ ADV PLUS * CLASSIC * PREMIER For use with members associated with the BHN Network Prior Authorization List 2015 Prior Authorization List 2015 Participating providers are responsible to furnish or arrange health care services with other participating healthcare facilities or providers. Prior authorization requests

More information

MedStar Medicare Choice Pharmacy Services

MedStar Medicare Choice Pharmacy Services Pharmacy Services 1 MedStar Medicare Choice Pharmacy Services Table of Contents At a Glance..page 2 Pharmacy Policies..page 4 Medicare Choice Pharmacy Programs..page 6 Where to Obtain Prescriptions..page

More information

SPECIALTY PHARMACY Master Clinical Drug List

SPECIALTY PHARMACY Master Clinical Drug List Abraxane J9264 Provider ONCOLOGY None NO Actemra J3262 Provider ARTHRITIS PA - all YES Acthar HP Gel J0800 Prov/Self Med/Pharm ENDOCRINE/METABOLIC PA - all YES Adagen J2504 Provider ENZYME DISORDERS None

More information

Injections Requiring Prior Authorization

Injections Requiring Prior Authorization At VIVA Health, we strive to keep our provider network informed of any changes. Most of you may currently obtain prior authorizations for administered injections. Below is a list of injection, infusion,

More information

J1556 INJECTION, IMMUNE GLOBULIN (BIVIGAM) 500 MG $ J1559 INJECTION, IMMUNE GLOBULIN (HIZENTRA) 100 MG $14.364

J1556 INJECTION, IMMUNE GLOBULIN (BIVIGAM) 500 MG $ J1559 INJECTION, IMMUNE GLOBULIN (HIZENTRA) 100 MG $14.364 G0333 INITIAL 30-DAY SUPPLY AS A BENEFICIARY $57.000 J0133 INJECTION, ACYCLOVIR 5 MG $0.470 J0285 INJECTION, AMPHOTERICIN B 50 MG $10.280 J0287 INJECTION, AMPHOTERICIN B LIPID COMPLEX 10 MG $21.850 J0288

More information

The following are J Code requirements

The following are J Code requirements The following are J Code requirements J Codes 20610 Arthrocentesis, aspiration and/or injection; major joint or bursa (eg, shoulder, hip, knee joint, subacromial bursa) A9579 Injection, gadolinium based

More information

DME MAC Jurisdiction C Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2018 through 03/31/2018

DME MAC Jurisdiction C Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2018 through 03/31/2018 G0333 PHARMACY DISPENSING FEE FOR INHALATION DRUG(S); INITIAL 30-DAY SUPPLY AS A BENEFICIARY $57.000 J0133 INJECTION, ACYCLOVIR 5 MG $0.068 J0285 INJECTION, AMPHOTERICIN B 50 MG $32.987 J0287 INJECTION,

More information

DME MAC Jurisdiction B Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2019 through 03/31/2019

DME MAC Jurisdiction B Drug Fees, Pharmacy Dispensing Fees and Pharmacy Supply Fees Effective 01/01/2019 through 03/31/2019 G0333 PHARMACY DISPENSING FEE FOR INHALATION DRUG(S); INITIAL 30-DAY SUPPLY AS A BENEFICIARY $57.000 J0133 INJECTION, ACYCLOVIR 5 MG $0.048 J0285 INJECTION, AMPHOTERICIN B 50 MG $31.668 J0287 INJECTION,

More information

RAHF PFM ALPHANINE SD COAGULATION FACTOR IX J7193 COAGULATION FACTOR IX (RFIXFC)

RAHF PFM ALPHANINE SD COAGULATION FACTOR IX J7193 COAGULATION FACTOR IX (RFIXFC) INFECTIOUS DISEASE ACTIMMUNE INTERFERON GAMMA 1B J9216 ADVATE RAHF PFM ONCOLOGY ORAL AFINITOR EVEROLIMUS J7527 INFECTIOUS DISEASE ALFERON N INTERFERON ALFA N3 J9215 ALPHANATE VWF J7186 ALPHANINE SD J7193

More information

Part B payment for drugs in Medicare 0

Part B payment for drugs in Medicare 0 Part B payment for drugs in Medicare 0 Introduction: The recent pilot proposal 1 on Part B drug payment from the Center for Medicare and Medicaid Innovation of CMS has met strong resistance 2 from the

More information

Part B payment for drugs in Medicare: Phase 1 of CMS s proposed pilot and its impact on oncology care

Part B payment for drugs in Medicare: Phase 1 of CMS s proposed pilot and its impact on oncology care Part B payment for drugs in Medicare: Phase 1 of CMS s proposed pilot and its impact on oncology care Raina H. Jain, Stephen M. Schleicher, Coral L. Atoria, Peter B. Bach Executive Summary The recent pilot

More information

Table III: 2019 Medicare Drug Fee Schedule* CY st Quarter Average Sales Price (ASP) Data Plus 6 Percent

Table III: 2019 Medicare Drug Fee Schedule* CY st Quarter Average Sales Price (ASP) Data Plus 6 Percent Table III: 2019 Medicare Drug Fee Schedule* CY 2019 1st Quarter Average Sales Price (ASP) Data Plus 6 Percent *The Medicare payments allowance limits are effective Jan. 1 thru March. 31, 2019. CY 2019

More information

J-Code Trade Name Drug Name Required Medical Information

J-Code Trade Name Drug Name Required Medical Information FIDELIS CARE NEW YORK DEPARTMENT OF PHARMACY SERVICES Updated: 10/31/2017 J-Code Prior Authorizations & Required Clinical Information Medicaid, Child Health Plus, HealthierLife, Metal-Level J-Code Trade

More information

2014 AlohaCare Advantage (HMO) and AlohaCare Advantage Plus Formulary (HMO SNP) Drugs with Prior Authorization Requirements

2014 AlohaCare Advantage (HMO) and AlohaCare Advantage Plus Formulary (HMO SNP) Drugs with Prior Authorization Requirements 2014 AlohaCare Advantage (HMO) and AlohaCare Advantage Plus Formulary (HMO SNP) with Prior Authorization Requirements You may need prior authorization for certain drugs that are on the formulary or drugs

More information

Drug Use Evaluation: Physician Administered Drugs (PADs)

Drug Use Evaluation: Physician Administered Drugs (PADs) Drug Use Research & Management Program OHA Division of Medical Assistance Programs 500 Summer Street NE, E35; Salem, OR 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Drug Use Evaluation: Physician Administered

More information

High Risk Medications

High Risk Medications Department Policy Code: D: MM-5705 Entity: Fairview Health Services Department: Home Infusion Manual: Policies & Procedures Category: Medication Management Subject: High Risk Medications Purpose: To provide

More information

FIDELIS CARE NEW YORK DEPARTMENT OF PHARMACY SERVICES J Code Prior Authorizations & Required Clinical Information 2011 (Updated 3/14/11)

FIDELIS CARE NEW YORK DEPARTMENT OF PHARMACY SERVICES J Code Prior Authorizations & Required Clinical Information 2011 (Updated 3/14/11) FIDELIS CARE NEW YORK DEPARTMENT OF PHARMACY SERVICES J Code Prior Authorizations & Required Clinical Information 2011 (Updated 3/14/11) Brand Generic J Code Covered Uses Required Medical Information and

More information

Part B payment for drugs in Medicare 0

Part B payment for drugs in Medicare 0 Part B payment for drugs in Medicare 0 Introduction: The recent pilot proposal 1 on Part B drug payment from the Center for Medicare and Medicaid Innovation of CMS has met strong resistance 2 from the

More information

LIST OF DRUGS THAT MAY BE COVERED UNDER YOUR MEDICAL BENEFIT

LIST OF DRUGS THAT MAY BE COVERED UNDER YOUR MEDICAL BENEFIT LIST OF DRUGS THAT MAY BE COVERED UNDER YOUR MEDICAL BENEFIT The following medications may be covered under your medical benefit if they are provided to you in your doctor s office or outpatient infusion

More information

INJECTABLE MEDICINES. Resources, Links or Additional Information. J Code Brand Names Generic names Prior Authorization or Restrictions

INJECTABLE MEDICINES. Resources, Links or Additional Information. J Code Brand Names Generic names Prior Authorization or Restrictions J9190 5-FU fluorouracil None. J0401 ABILIFY MAINTENA aripiprazole i.v. J9264 ABRAXANE paclitaxel protein bound J3262 ACTEMRA IV tocilizumab Yes, through Navitus. Restricted to (in at least consultation

More information

Aetna Better Health. Specialty Drug Program

Aetna Better Health. Specialty Drug Program Aetna Better Health is managed through CVS Health Specialty Pharmacy. The Specialty pharmacies fill prescriptions and ship drugs for complex medical conditions, including multiple sclerosis, rheumatoid

More information

Pharmacy Services Request Types

Pharmacy Services Request Types FOR DRUG REQUESTS, ONLY-- * NOTE: Only those drugs administered by a healthcare provider and billed medically would be entered via CareAffiliate. * Oral drugs would not be administered by a healthcare

More information

Highmark List of Procedure Codes Requiring NDC Effective 12/01/2017

Highmark List of Procedure Codes Requiring NDC Effective 12/01/2017 90378 RESPIRATORY SYNCYTIAL VIRUS, MONOCLONAL ANTIBODY, RECOMBINANT, FOR INTRAMUSCULAR USE, 50 MG, EACH C9399 Unclassified Drugs or biologicals J0129 INJECTION, ABATACEPT, 10 MG J0130 INJECTION ABCIXIMAB,

More information

Drug Name Tier Drug Name Tier

Drug Name Tier Drug Name Tier Drug Name Tier Drug Name Tier ABELCET 100 MG/20 ML VIAL 4 ACETYLCYSTEINE 10% VIAL 2 ACETYLCYSTEINE 20% VIAL 2 ACYCLOVIR 1,000 MG/20 ML VIAL 2 ACYCLOVIR 500 MG/10 ML VIAL 2 ADRUCIL 500 MG/10 ML VIAL 2 ALBUTEROL

More information

Injectable Drugs Requiring Pre-Service Approval

Injectable Drugs Requiring Pre-Service Approval Abatacept Orencia J0129, 10 mg 1500 FL LCD- L29051 1) For patients with rheumatoid arthritis with failure, intolerance or contraindications to methotrexate. Limit dosing to 40 mg Q 2 weeks. 2) For patients

More information

Original Policy Date

Original Policy Date MP 5.01.17 Specialty Drugs Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/ Date Local policy Last updated/12:2013 Return to Medical Policy Index

More information

Committee Approval Date: December 12, 2014 Next Review Date: July 2015

Committee Approval Date: December 12, 2014 Next Review Date: July 2015 Medication Policy Manual Policy No: dru378 Topic: Akynzeo, netupitant/palonosetron Date of Origin: December 12, 2014 Committee Approval Date: December 12, 2014 Next Review Date: July 2015 Effective Date:

More information

New Billing Guidelines for Home Infusion, Enteral and Parenteral Therapies Home Infusion Fee Schedule Effective July 1, 2009

New Billing Guidelines for Home Infusion, Enteral and Parenteral Therapies Home Infusion Fee Schedule Effective July 1, 2009 STAT Bulletin PO Box 80 Buffalo, New York 14240-0080 May 12, 2009 Volume 15:Issue 18 To: All Home Health Care and Home Infusion Therapy Providers Contracts Effected: All Lines of Business New Billing Guidelines

More information

Fee* Effective CPT Code Short Description

Fee* Effective CPT Code Short Description 90281 HUMAN IG, IM $70.38 90283 HUMAN IG, IV $42.84 90284 HUMAN IG, SC $10.71 90291 CMV IG, IV $1,311.21 90371 HEP B IG, IM $131.58 90375 RABIES IG, IM/SC $307.53 90376 RABIES IG, HEAT TREATED $338.13

More information

MDwise Self-Administered Codes for Medical

MDwise Self-Administered Codes for Medical The following codes are associated with medications that can be self-administered by the patient or a caregiver. As a result, MDwise will transfer coverage of these self-administered medications exclusively

More information

Primary malignant neoplasms, not lymphatic or hematopoietic. Secondary malignant neoplasms (i.e.metastatic) Malignant neoplasm, unknown site

Primary malignant neoplasms, not lymphatic or hematopoietic. Secondary malignant neoplasms (i.e.metastatic) Malignant neoplasm, unknown site Supplementary Table 1. ICD-9-CM codes used to define cancer ICD-9 Diagnosis code 140.xx-172.xx 174.xx-195.xx 196.xx 198.xx 199.xx 200.xx-208.xx Description Primary malignant neoplasms, not lymphatic or

More information

2016 MDwise HIP Medical Services that Require Prior Authorization

2016 MDwise HIP Medical Services that Require Prior Authorization 2016 MDwise HIP Medical Services that Require Prior Authorization Medical services that require Prior Authorization Type of Service Requires PA Coding All Out of Network services Facility to facility ambulance

More information

HCPCS Code/ generic (Brand) Name J7506. J8520 capecitabine (Xeloda) 1. J8521 capecitabine. J8530 cyclophosphamide. (Cytoxan) 1

HCPCS Code/ generic (Brand) Name J7506. J8520 capecitabine (Xeloda) 1. J8521 capecitabine. J8530 cyclophosphamide. (Cytoxan) 1 drug and administration compendia Current Price () J7506 Prednisone, oral, per 5 mg 12/1/07 $0.07 $0.19 N/A prednisone 2 J8520 capecitabine (Xeloda) 1 Capecitabine, oral, 150 mg 8/1/07 $5.79 $4.59 N/A

More information

Fee* Effective CPT Code Short Description 02/15/2017

Fee* Effective CPT Code Short Description 02/15/2017 90281 HUMAN IG, IM $70.38 90283 HUMAN IG, IV $45.14 90284 HUMAN IG, SC $11.48 90291 CMV IG, IV $1,311.21 90371 HEP B IG, IM $131.58 90375 RABIES IG, IM/SC $307.53 90376 RABIES IG, HEAT TREATED $368.73

More information

STAT Bulletin. Drug Therapy Guideline Updates. To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business

STAT Bulletin. Drug Therapy Guideline Updates. To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business STAT Bulletin November 28, 2011 Volume 9: Issue 27 To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business Drug Therapy Guideline Updates Why you re receiving this Stat

More information

Billing for Infusion Services in an Outpatient Neurology Clinic. Christine Mann, MBA Director of Infusion Services Dent Neurologic Institute

Billing for Infusion Services in an Outpatient Neurology Clinic. Christine Mann, MBA Director of Infusion Services Dent Neurologic Institute Billing for Infusion Services in an Outpatient Neurology Clinic Christine Mann, MBA Director of Infusion Services Dent Neurologic Institute Overview of Infusion Billing Codes Current Procedure Terminology

More information

CPT Service Description Effective Date

CPT Service Description Effective Date Medical Oncology Program Review Code List 2 nd Quarter 2018 This list is subject to change once per quarter. Changes will be posted to the BCBSNC website at www.bcbsnc.com by the 10th day of January, April,

More information

INJECTION, INOTUZUMAB OZOGAMICIN, 0.1 MG [BESPONSA ] [C CODES FOR FACILITY USE ONLY]

INJECTION, INOTUZUMAB OZOGAMICIN, 0.1 MG [BESPONSA ] [C CODES FOR FACILITY USE ONLY] Commercial Medical Oncology Program Review Code List 3rd Quarter 2018 This list is subject to change once per quarter. Changes will be posted to the BCBSNC website at www.bcbsnc.com by the 10th day of

More information

Medicare Part B Covered Medications

Medicare Part B Covered Medications This table provides a reference guide for the most frequent Part B/D coverage determination scenarios facing Part D plans and Part D pharmacy providers. It does not address all potential situations. For

More information

MDwise HIP Prior Authorization and Drug List

MDwise HIP Prior Authorization and Drug List MDwise HIP Prior Authorization and Drug List Services that require Prior Authorization Type of Service Requires PA Coding All Out of Network services With the exception of ER, Ambulance, Urgent Care Center

More information

ELECTRONIC HEALTH RECORD (EHR) ENHANCEMENTS FOR MARCH 15, 2016 SUMMARY

ELECTRONIC HEALTH RECORD (EHR) ENHANCEMENTS FOR MARCH 15, 2016 SUMMARY ELECTRONIC HEALTH RECORD (EHR) ENHANCEMENTS FOR MARCH 15, 2016 SUMMARY Problem Opening PACS Images on ipads or ibooks has Been Fixed Changes have been made in PROD to enable user credentials to be passed

More information

Injectables/Medications Administered Under the Medical Benefit Authorization NOT Required List Effective 04/01/2017

Injectables/Medications Administered Under the Medical Benefit Authorization NOT Required List Effective 04/01/2017 Injectables/Medications Administered Under the Medical Benefit Authorization NOT Required List Effective 04/01/2017 NOTES: Claims payment is subject to member eligibility, benefit coverage and current

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION Table S1 Therapeutic biologic product approvals, classes and innovation categories: 16 24 Approval year Trade name Active Ingredient(s) Drug class Innovation category Approval date 16 Intron-A Interferon

More information

PRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION

PRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION Abstral fentanyl citrate oral tablet Controlled Dangerous substance Actemra tocilizumab Monoclonal antibody Acthar corticotropin Hormone Actimmune interferon gamma 1b Interferon Actiq fentanyl citrate

More information

PA Category Name Code(s) Additional Notes ABA 0364T 0365T 0366T 0367T 0373T 0374T H G0396. Applied Behavioral Analysis stage 3*

PA Category Name Code(s) Additional Notes ABA 0364T 0365T 0366T 0367T 0373T 0374T H G0396. Applied Behavioral Analysis stage 3* ABA BEHAVIORAL HEALTH CHEMICAL DEPENDENCY Applied Behavioral Analysis stage 3* Neuropsychological Testing Chemical Dependency/Substance Abuse* (MA Only) 0364T 0365T 0366T 0367T 0373T 0374T H2020 96116

More information

Utilization Management

Utilization Management Abraxane Abraxane Actemra (IV) Inflammatory Conditions PA/Step Actemra (SQ) Inflammatory Conditions PA/Step Acthar HP Miscellaneous CNS Disorders PA Actimmune NF Adcetris Adcirca Adempas Advate (all forms)

More information

2016 MDwise HIP Medical Services that Require Prior Authorization

2016 MDwise HIP Medical Services that Require Prior Authorization 2016 MDwise HIP Medical Services that Require Prior Authorization Medical services that require Prior Authorization Type of Service Coding All Out of Network services Facility to facility ambulance transport

More information

2018 MDwise Excel Network Hoosier Healthwise Medical Services that Require Prior Authorization

2018 MDwise Excel Network Hoosier Healthwise Medical Services that Require Prior Authorization 2018 MDwise Excel Network Hoosier Healthwise Medical Services that Require Prior Authorization Medical services that require Prior Authorization Type of Service Requires PA Coding All Out of Network services

More information

To help doctors give their patients the best possible care, the American

To help doctors give their patients the best possible care, the American Patient Information Resources from ASCO What to Know ASCO s Guideline on Preventing Vomiting Caused by Cancer Treatment SEPTEMBER 2011 KEY MESSAGES The risk of nausea and vomiting depends on the specific

More information

Pharmacy and Medical Guideline Updates

Pharmacy and Medical Guideline Updates STAT Bulletin PO Box 15013 Albany, New York 12212 August 2, 2010 Volume 8: Issue 19 To: All PCPs and Specialists Contracts Affected: All Lines of Business Pharmacy and ical Guideline Updates As a result

More information

MDwise Hoosier Care Connect Medical Services that Require Prior Authorization

MDwise Hoosier Care Connect Medical Services that Require Prior Authorization MDwise Hoosier Care Connect Medical Services that Require Prior Authorization Certain Indiana Health Coverage Programs (IHCP) services require prior authorization (PA) for members enrolled in the Hoosier

More information

Leukemia. Treatment of. compendia. Associated ICD-9-CM Codes: Drug & Administration. managedcareoncology.com

Leukemia. Treatment of. compendia. Associated ICD-9-CM Codes: Drug & Administration. managedcareoncology.com Drug & compendia Treatment of Leukemia With each publication, Managed Care Oncology s Drug & Compendia highlights a single medication or a group of medications that could be utilized in the management

More information

2018 MDwise Excel Network Hoosier Healthwise Medical Services that Require Prior Authorization

2018 MDwise Excel Network Hoosier Healthwise Medical Services that Require Prior Authorization 2018 MDwise Excel Network Hoosier Healthwise Medical Services that Require Prior Authorization Medical services that require Prior Authorization Type of Service Requires PA Coding All Out of Network services

More information

List of Designated High-Cost Drugs

List of Designated High-Cost Drugs List of Designated High-Cost Drugs UPDATED APRIL 25, 2018 For details on the High-Cost Drug policy, see Section 5.8 of the PharmaCare Policy Manual. Recent updates appear in red. Deletions are listed at

More information

BCN Advantage SM requirements for drugs covered under the medical benefit

BCN Advantage SM requirements for drugs covered under the medical benefit J0586 ABOBOTULINUMTOXINA Dysport X X X the medication is being used to treat J0178 AFLIBERCEPT Eylea X X X X X of Neovascular (Wet) -Related Macular Degeneration of Macular Edema following either central

More information

PA Category Name Code(s) Additional Notes ABA. Applied Behavioral Analysis stage 3*

PA Category Name Code(s) Additional Notes ABA. Applied Behavioral Analysis stage 3* ABA BEHAVIORAL HEALTH CHEMICAL DEPENDENCY Applied Behavioral Analysis stage 3* Neuropsychological Testing Chemical Dependency/Substance Abuse* (MA Only) 0373T H2020 96116 96112 96113 96121 96130 96131

More information

ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced

ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced Class Medicine Name Nappi Strength Form Size Route Abiraterone Acetate ZYTIGA

More information

2017 MDwise HIP Medical Services that Require Prior Authorization

2017 MDwise HIP Medical Services that Require Prior Authorization 2017 MDwise HIP Medical Services that Require Prior Authorization Medical services that require Prior Authorization Type of Service Requires PA Coding All Out of Network services Facility to facility ambulance

More information

Subject: Fosnetupitant-Palonosetron (Akynzeo) IV

Subject: Fosnetupitant-Palonosetron (Akynzeo) IV 09-J3000-01 Original Effective Date: 06/15/18 Reviewed: 05/09/18 Revised: 01/01/19 Subject: Fosnetupitant-Palonosetron (Akynzeo) IV THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,

More information

LDI integrated pharmacy services

LDI integrated pharmacy services 8 ARRANON CARIMUNE NF Immunodeficiency 8-MOP Psoriasis ARZERRA CAYSTON Cystic Fibrosis A ASTAGRAF XL Antirejection CERDELGA Gaucher's Disease abacavir ATRIPLA CEREZYME Gaucher's Disease abacavir/lamivudine/

More information

Subject: Palonosetron Hydrochloride (Aloxi )

Subject: Palonosetron Hydrochloride (Aloxi ) 09-J0000-87 Original Effective Date: 02/15/09 Reviewed: 07/09/14 Revised: 03/15/18 Subject: Palonosetron Hydrochloride (Aloxi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION

More information

Positively Affecting the Lives of Members Each and Every Day. Volume 14 May Specialty Drug News

Positively Affecting the Lives of Members Each and Every Day. Volume 14 May Specialty Drug News Positively Affecting the Lives of Members Each and Every Day LDI Volume 14 May 2008 Specialty Drug News 2008 Medications to Watch 1. Respiratory syncytial virus (RSV) Numax (motavizumab) Respiratory syncytial

More information

STAT Bulletin. Drug Therapy Guideline Updates. To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business

STAT Bulletin. Drug Therapy Guideline Updates. To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business STAT Bulletin November 28, 2011 Volume 17: Issue 34 To: All Primary Care Physicians and Specialists Contracts Affected: All Lines of Business Drug Therapy Guideline Updates Why you re receiving this Stat

More information

Quarterly Pharmacy Formulary Change Notice

Quarterly Pharmacy Formulary Change Notice Quarterly Pharmacy Formulary Change Notice Summary of Change: The formulary changes listed in the table below were reviewed and approved at our December 18, 2014 Value Assessment Committee (VAC) meeting.

More information

A9542 A9543 A9545 A9699 J0120 J0128 J0129 J0130

A9542 A9543 A9545 A9699 J0120 J0128 J0129 J0130 Procedure Code 90378 A9542 A9543 Procedure Description Long RESPIRATORY SYNCYTIAL VIRUS IMMUNE GLOBULIN (RSV-IGIM), FOR INTRAMUSCULAR USE, 50 MG, EACH INDIUM IN-111 IBRITUMOMAB TIUXETAN, DIAGNOSTIC, PER

More information

Percent Brand Name Generic Name Strength How Supplied NDC from AWP/SWP Adcetris. Amprya dalfampridine 10 mg 60 count bottle

Percent Brand Name Generic Name Strength How Supplied NDC from AWP/SWP Adcetris. Amprya dalfampridine 10 mg 60 count bottle Department of General Services Procurement Division Contract # 01-14- 65-57 Pharmaceutical Acquisitions Section Exhibit G-1 April 30, 2015 Walgreens Specialty Pharmacy LLC, Products Pricing Crescent Healthcare,

More information

Medication Prior Authorization Form

Medication Prior Authorization Form Section I Member Information Name (Last, First, Middle Initial) Date of Birth WEA Trust Subscriber Number Diagnosis Page 2 1. MEDICATION 2. STRENGTH 3. DIRECTIONS 4. QUANTITY FEIBA NF NovoSeven RT HEMOFIL

More information

2018 MDwise HIP Medical Services that Require Prior Authorization

2018 MDwise HIP Medical Services that Require Prior Authorization 2018 MDwise HIP Medical Services that Require Prior Authorization Medical services that require Prior Authorization Type of Service Requires PA Coding All Out of Network services Facility to facility ambulance

More information

Medical Prior Authorization List Rosen Employee Plans For prescription drug requirements, contact EHIM toll-free at

Medical Prior Authorization List Rosen Employee Plans For prescription drug requirements, contact EHIM toll-free at For prescription drug requirements, contact EHIM toll-free at 1.800.311.3446. General Information These requirements are administered by Health First Health Plans ( Health Plan ). Benefits are determined

More information

Medications currently available to treat Multiple Myeloma include: Current Code Price (AWP) Effective Date. Code Price (AWP)

Medications currently available to treat Multiple Myeloma include: Current Code Price (AWP) Effective Date. Code Price (AWP) drug and administration compendia Compendia information developed and maintained by With each publication Managed Care Oncology s Drug & Compendia will highlight a single medication or a group of medications

More information

2018 MDwise HIP Medical Services that Require Prior Authorization

2018 MDwise HIP Medical Services that Require Prior Authorization 2018 MDwise HIP Medical Services that Require Prior Authorization Medical services that require Prior Authorization Type of Service Requires PA Coding All Out of Network services Facility to facility ambulance

More information

2018 MDwise HIP Medical Services that Require Prior Authorization

2018 MDwise HIP Medical Services that Require Prior Authorization 2018 MDwise HIP Medical Services that Require Prior Authorization Medical services that require Prior Authorization Type of Service Requires PA Coding All Out of Network services Facility to facility ambulance

More information

Descriptor Brand Name. Alprostadil, Caverject, Edex, Prostin VR Pediatric. Calcimar, Miacalcin

Descriptor Brand Name. Alprostadil, Caverject, Edex, Prostin VR Pediatric. Calcimar, Miacalcin Self-Administered Drug Exclusion List R2 This article from Medicare A News, Issue 2106 dated January 23, 2013 and Medicare B News, Issue 283 dated January 23, 2013 is being revised to add Acthar ACTH gel

More information

Formulary Chemotherapy Agents: (Current as of 6/2018) Therapeutic Class

Formulary Chemotherapy Agents: (Current as of 6/2018) Therapeutic Class MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY Cancer LAST REVIEW 9/11/18 THERAPEUTIC CLASS Oncology REVIEW HISTORY 5/17, 5/16 LOB AFFECTED Medi-Cal (MONTH/YEAR) This policy

More information

Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A

Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A Supportive Care in Cancer Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A Systematic Review of the Medicare Database Romina Sosa, Shuling Li, Julia T. Molony, Jiannong

More information

Acute Lymphocytic Leukemia

Acute Lymphocytic Leukemia Acute Lymphocytic Leukemia Splenectomy (Removal of Spleen) 6-Mercaptopurine (Purinethol, 6-MP) Alemtuzumab (Campath ) Arsenic Trioxide (Trisenox ) Bendamustine (Treanda ) Bexarotene (Targretin ) Bleomycin

More information

How Safe and Innovative Are First-in-Class Drugs Approved by Health Canada: A Cohort Study

How Safe and Innovative Are First-in-Class Drugs Approved by Health Canada: A Cohort Study RESEARCH PAPER How Safe and Are First-in-Class Drugs Approved by Health Canada: A Cohort Study L innocuité et l aspect innovant des nouvelles classes de médicaments approuvés par Santé Canada : une étude

More information

Corporate Medical Policy

Corporate Medical Policy Antiemetic Injection Therapy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: antiemetic_injection_therapy 5/2015 3/2017 3/2018 3/2017 Description of Procedure

More information

Medication Policy Manual. Policy No: dru408. Topic: Site of Care Review Date of Origin: July 10, 2015

Medication Policy Manual. Policy No: dru408. Topic: Site of Care Review Date of Origin: July 10, 2015 Medication Policy Manual Policy No: dru408 Topic: Site of Care Review Date of Origin: July 10, 2015 Committee Approval Date: August 17, 2018 Next Review Date: August 2019 Effective Date: October 1, 2018

More information

PRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION

PRESCRIPTION DRUGS REQUIRING PRIOR AUTHORIZATION Abstral fentanyl citrate oral tablet Controlled Dangerous substance Actemra tocilizumab Monoclonal antibody Acthar corticotropin Hormone Actimmune interferon gamma 1b Interferon Actiq fentanyl citrate

More information

Prior Auth Form Page Number

Prior Auth Form Page Number Prior Auth Form Page Number B vs D Oral Anti-Cancer 3 B vs D Oral Anti-Emetic 4 B vs D Oral Anti-rejection/Transplant 5 J0129 Abatacept, inj Orencia 6 J0180 Agalsidase beta injection Fabrazyme 7 J0205

More information

Client Prior Authorization Program (CPA) PA Required (PA) Reimb Code. Reimb Code CLAIM EDIT. Reimb Code. Reimb Code. Reimb Code

Client Prior Authorization Program (CPA) PA Required (PA) Reimb Code. Reimb Code CLAIM EDIT. Reimb Code. Reimb Code. Reimb Code Medical Benefit Management Specialty Drug List Effective October 1, 2015 The symbol [] next to a drug name indicates that this medication is subject to the Prior. The symbol [C] next to a drug name indicates

More information

of our members each and

of our members each and s p e c i a l t y d r u g n e w s Positively affecting the lives of our members each and every day Efalizumab (Raptiva ) Withdrawn from US Market On April 9, 2009 Genentech, Inc. announced that it is undergoing

More information

Prior Authorization Program

Prior Authorization Program Prescription Drug List January 2011 Prior Authorization Program The prior authorization program helps us offer broad prescription drug coverage and promotes safe, clinically appropriate drug usage. Under

More information

MEDICAL NECESSITY GUIDELINE

MEDICAL NECESSITY GUIDELINE PAGE: 1 of 10 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted

More information

Ovarian Cancer. compendia TREATMENT OF

Ovarian Cancer. compendia TREATMENT OF drug & compendia TREATMENT OF Ovarian Cancer With each publication, ManagedCare Oncology s drug & Compendia highlights a single medication or a group of medications that could be utilized in the management

More information

Subject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi )

Subject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi ) 09-J2000-60 Original Effective Date: 06/15/16 Reviewed: 04/11/18 Revised: 01/01/19 Subject: NK-1 receptor antagonist injectable therapy (Emend, Cinvanti, Varubi ) THIS MEDICAL COVERAGE GUIDELINE IS NOT

More information

RETIRED. Maximum Drug Dose Policy

RETIRED. Maximum Drug Dose Policy RETIRED DRUG POLICY Policy Number 2017D0034A Maximum Drug Dose Policy Annual Approval Date 3/1/2017 Approved By UnitedHealthcare National Pharmacy & Therapeutics Committee United Healthcare Community Plan

More information

Prescription Drug Benefit Rider V

Prescription Drug Benefit Rider V Prescription Drug Benefit Rider V Your Certificate of Coverage is amended as described in this document. This Rider becomes a part of your Certificate of Coverage and is subject to all provisions of your

More information

Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients

Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients Guidelines on Chemotherapy-induced Nausea Vomiting in Pediatric Cancer Patients COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For

More information

1 17 ACITRETIN 10MG CAP 20, ,000 14,000 4, ACITRETIN 25MG CAP 50, ,000 35,000 10,000

1 17 ACITRETIN 10MG CAP 20, ,000 14,000 4, ACITRETIN 25MG CAP 50, ,000 35,000 10,000 ردیف کد ژنریک نام ژنریک مبلغ پوشش وزارت بهداشت مبلغ پوشش بیمه مبلغ پرداخت بیمار درصد پرداخت بیمار قیمت اعالمی وزارت بهداشت نام تجاری 1 17 ACITRETIN 10MG CAP 20,000 10.0 2,000 14,000 4,000 2 18 ACITRETIN

More information

Prescription Drug Benefit Rider

Prescription Drug Benefit Rider Prescription Drug Benefit Rider Your Certificate of Coverage is amended as described in this document. This Rider becomes a part of your Certificate of Coverage and is subject to all provisions of your

More information

Brand Generic J-Code 1 Billable. Exclusion Criteria. Information and Criteria. Unit

Brand Generic J-Code 1 Billable. Exclusion Criteria. Information and Criteria. Unit Affinity Health Plan Department Of Pharmacy (Medicaid, Child Health Plus, Family Health Plus, Medicare Part B) **Medications Requiring Authorization under Medical Benefit** Click Here For Medication Authorization

More information

March 2017 Pharmacy & Therapeutics Committee Decisions

March 2017 Pharmacy & Therapeutics Committee Decisions UCare s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to the UCare formulary (approved drug list). These changes are reviewed

More information